en · de · es · pt
sr9009-notes.peptides9002.com › Info › Analytical Detection And Regulatory Status — Evidence Review

Analytical Detection And Regulatory Status — Evidence Review

By Editorial Desk · published 2025-11-26 · last reviewed 2025-12-20 · Info

REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved for human useInvestigational status in most countries
Sports statusProhibited by WADAClassified as non-approved or metabolic modulator
Common analytical methodLC-MS/MSUsed for trace detection in biological samples
Typical test matricesUrine and bloodSample choice depends on testing program
Human trial dataNone publishedEffects and safety are not established

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Related pages on this site

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Reference notes

==== X-ray spectroscopy ==== X-ray spectroscopy methods can be used for genuine operando analyses of catalysts and other functional materials. The redox dynamics of sulfur with Ni/GDC anode during solid oxide fuel cell (SOFC) operation at mid- and low-range temperatures in an operando S K-edge XANES have been studied. Ni is a typical catalyst material for the anode in high temperature SOFCs. The operando spectro-electrochemical cell for this high temperature gas-solid reaction study under electrochemical conditions was based on a typical high temperature heterogeneous catalysis cell, which was further equipped with electric terminals. Very early method development for operando studies on PEM-FC fuel cells was done by Haubold et al. at Forschungszentrum Jülich and HASYLAB. Specifically they developed plexiglas spectro-electrochemical cells for XANES, EXAFS and SAXS and ASAXS studies with control of the electrochemical potential of the fuel cell. Under operation of the fuel cell they determined the change of the particle size of and oxidation state and shell formation of the platinum electrocatalyst. In contrast to the SOFC operation conditions, this was a PEM-FC study in liquid environment under ambient temperature. The same operando method is applied to battery research and yields information on the changes of the oxidation state of electrochemically active elements in a cathode such as Mn via XANES, information on coronation shell and bond length via EXAFS, and information on microstructure changes during battery operation via ASAXS.

== Further reading == "New Guidelines Seek to Provide Clarity on Food Expiration Dates". All Things Considered. U.S.: NPR. 17 February 2017. Includes a list of the many terms used in the United States food industry. Anonymous, "Cold Chain Management", 2003, 2006 Anonymous, Protecting Perishable Foods During Transport by Truck Archived 2014-05-16 at the Wayback Machine, USDA Handbook 669, 1995 Kilcast, D., Subramamiam, P., Food and Beverage Stability and Shelf Life, Woodhead Publishing, 2011, ISBN 978-1-84569-701-3 Labuza, T. P., Szybist, L., Open dating of Foods, Food and Nutrition Press, 2001; other edition: Wiley-Blackwell, 2004, ISBN 0-917678-53-2 Man, C. M., Jones. A. A., Shelf-Life Evaluation of Foods, ISBN 0-8342-1782-1 Robertson, G.L., Food Packaging and Shelf Life: A Practical Guide, CRC Press, 2010, ISBN 978-1-4200-7844-2 Steele, R., Understanding and Measuring the Shelf-Life of Food, Woodhead Publishing, 2004, ISBN 1-85573-732-9 Weenen, H., Cadwallader, K., Freshness and Shelf Life of Foods, ACS, 2002, ISBN 0-8412-3801-4

According to the Substance Abuse and Mental Health Services Administration's National Survey on Drug Use and Health, in 2016 more than 11 million Americans misused prescription opioids, nearly 1 million used heroin, and 2.1 million had an addiction to prescription opioids or heroin. While rates of overdose of legal prescription opiates have leveled off in the past decade, overdoses of illicit opiates have surged since 2010, nearly tripling. In a 2015 report, the US Drug Enforcement Administration stated that "overdose deaths, particularly from prescription drugs and heroin, have reached epidemic levels." Nearly half of all opioid overdose deaths in 2016 involved prescription opioids. From 1999 to 2008, overdose death rates, sales, and substance use disorder treatment admissions related to opioid pain relievers all increased substantially. By 2015, there were more than 50,000 annual deaths from drug overdose, causing more deaths than either car accidents or guns. In 2016, around 64,000 Americans died from overdoses, 21 percent more than the approximately 53,000 in 2015. By comparison, the figure was 16,000 in 2010, and 4,000 in 1999. While death rates varied by state, in 2017 public health experts estimated that nationwide over 500,000 people could die from the epidemic over the next 10 years. In Canada, half of the overdoses were accidental, while a third were intentional. The remainder were unknown. Many of the deaths are from an extremely potent opioid, fentanyl, which is trafficked from Mexico. The epidemic cost the United States an estimated $504 billion in 2015.

Sources: en.wikipedia.org

Notes from published material

== Etiology == The etiology of anxiety disorder remains unknown. There are several contributing factors that are yet to be proved to cause anxiety disorders. These factors include childhood anxiety, drug induction by central stimulant drugs, metabolic diseases or having depressive disorder.

(death announced on this date) 14 October – Rosalind Howells, Baroness Howells of St Davids, 94, British politician, member of the House of Lords (1999–2019). 20 October – Oliver Colvile, 66, British politician, MP (2010–2017). 25 October – Dick Taverne, 97, British politician, MP (1962–1974) and member of the House of Lords (1996–2025). 3 November – John Marshall, 85, British politician, MEP (1979–1989) and MP (1987–1997). 11 November – Helen Newlove, Baroness Newlove, 63, British community reform activist, member of the House of Lords (since 2010). 16 November – Mark Fisher, 81, British politician, minister for the arts (1997–1998) and MP (1983–2010). 17 November – David Pryce-Jones, 89, British conservative commentator, author and historian. 27 November – Peter Whittle, 64, British politician, member of the London Assembly (2016–2021), cancer. 28 November – Sir John Stanley, 83, British politician, MP (1974–2015). 8 December – Kate Allsop, 71, British politician, mayor of Mansfield (2015–2019). (death announced on this date) 17 December – Sir Patrick McNair-Wilson, 96, English politician, MP (1964–1966, 1968–1997). (death announced on this date) 30 December – Joe Byrne, 72, Northern Ireland politician, MLA (1998–2003, 2011–2015). 31 December – Mary Bradley, 83, Northern Irish politician, MLA (2003–2011). (death announced on this date)

Education for primary, secondary, and tertiary levels is mostly supported by the state. All institutions, public and private, must be registered with the Ministry of Education (MOE). English is the language of instruction in all public schools, and all subjects are taught and examined in English except for the "mother tongue" language paper. While the term "mother tongue" in general refers to the first language internationally, in Singapore's education system, it is used to refer to the second language, as English is the first language. Students who have been abroad for a while, or who struggle with their "Mother Tongue" language, are allowed to take a simpler syllabus or drop the subject. Education takes place in three stages: primary, secondary, and pre-university education, with the primary education being compulsory. Students begin with six years of primary school, which is made up of a four-year foundation course and a two-year orientation stage. The curriculum is focused on the development of English, the mother tongue, mathematics, and science. Secondary school lasts from four to five years, and is divided between Express, Normal (Academic), and Normal (Technical) streams in each school, depending on a student's ability level. The basic coursework breakdown is the same as in the primary level, although classes are much more specialised. Pre-university education takes place at either Junior Colleges (JCs) or the Millennia Institute (MI), over a period of two and three years respectively.

The complaint further alleged that the injections caused a permanent loss of mobility and function from which she never recovered, describing the use of the drug as a form of "chemical restraint" and outside the standard of care. The case highlights concerns about the off-label use of antipsychotics in elderly dementia patients, a practice for which the drug carries a black box warning from the FDA due to an increased risk of death. Billy Driver, Jr. is a California prisoner who has been involuntarily administered the long-acting injectable antipsychotic Invega Sustenna (paliperidone palmitate) since at least 2019. He has filed multiple federal civil rights lawsuits alleging the forced medication causes severe side effects, including gynecomastia, borderline diabetes, heart palpitations, chest pain, and kidney pain. In one suit, Driver v. Naranjo (filed January 2024), Driver alleged that psychiatrist Dr. Naranjo at the Richard J. Donovan Correctional Facility (RJD) in San Diego had twice threatened to use physical force if Driver continued to refuse the injections. A judge dismissed Driver v. Naranjo in February 2025, noting that Driver's involuntary medication was authorized by active court orders issued through California's Keyhea process. Since 2020, Driver has undergone six Keyhea hearings, at each of which a court found that if unmedicated he would be a danger to others, that he lacked insight into his own need for medication, and that he could not manage his own treatment.

Sources: en.wikipedia.org

Background from the literature

14-3-3 proteins are a family of conserved regulatory molecules that are expressed in all eukaryotic cells. 14-3-3 proteins have the ability to bind a multitude of functionally diverse signaling proteins, including kinases, phosphatases, and transmembrane receptors. More than 200 signaling proteins have been reported as 14-3-3 ligands. Elevated amounts of 14-3-3 protein in cerebrospinal fluid are usually a sign of rapid neurodegeneration; a common indicator of Creutzfeldt–Jakob disease.

== Radiation == The weak beta emission is stopped by the walls of laboratory glassware. Soft X-rays are emitted when the beta particles are stopped, but as long as the body is kept more than 30 cm away these should pose no problem. The primary hazard when working with technetium is inhalation of dust; such radioactive contamination in the lungs can pose a significant cancer risk.

Newer varieties are now pending regulatory approval in the US which are designed to work rapidly, but retain the same genetic structure as regular human insulin. Short-acting insulin includes regular insulin, which begins working within 30 minutes and is active about 5 to 8 hours. Intermediate-acting insulin includes NPH insulin, which begins working in 1 to 3 hours and is active for 16 to 24 hours. Long-acting insulin includes the analogues glargine U100 and detemir, each of which begins working within 1 to 2 hours and continues to be active, without major peaks or dips, for about 24 hours, although this varies in many individuals. Ultra-long acting insulin includes the analogues insulin glargine U300 and degludec, which begin working within 30 to 90 minutes and continues to be active for greater than 24 hours. Newer long-acting insulins, like insulin icodec and insulin efsitora alfa, are designed for once-weekly use. Studies show they provide similar blood sugar control to daily insulins, with a comparable risk of hypoglycemia, while offering a simpler dosing routine. Combination insulin products combine fast- and short-acting insulin with a longer-acting insulin like NPH insulin. The combination products begin to work with the shorter-acting insulin (5–15 minutes for fast-acting, and 30 minutes for short-acting), and remain active for 16–24 hours. There are several variations with different proportions of the mixed insulins (e.g., Novolog Mix 70/30 contains 70% aspart protamine [akin to NPH], and 30% aspart).

the Georgians) were expelled from these territories." The commission commented, "South Ossetia should not be recognised because the preconditions for statehood are not met." The commission further commented on Abkhazia that "Although it shows the characteristics of statehood, the process of state-building as such is not legitimate, as Abkhazia never had a right to secession." The commission concluded, "The aspirations of the South Ossetian people to self-determination were not fulfilled" in the 1990s, and "The aspirations of the Abkhaz people to self-determination were not fulfilled". The report noted that although Russia had its own interests in the region, Russia was awarded peacekeeping and mediating mandate, which made the peace settlement difficult. The report said that even Russian reports suggested there was evidence of Russian military assistance to separatist troops before August 2008. The commission suggested that incidents before the conflict probably "formed part of a concerted effort directed against Georgia which was orchestrated or actively condoned by the de facto authorities of the two breakaway territories." The commission noted "Both breakaway regions sought the assistance of Russia in the hope that they would receive support should armed hostilities break out, and consequently undermined efforts to defuse the crisis." The commission continued, "In this sense, their behaviour is hardly consistent with the provisions of Art.

==== Blindness and vision impairment ==== Since 2003, researchers have successfully transplanted corneal stem cells into damaged eyes to restore vision. "Sheets of retinal cells used by the team are harvested from aborted fetuses, which some people find objectionable." When these sheets are transplanted over the damaged cornea, the stem cells stimulate renewed repair, eventually restoring vision. The latest such development was in June 2005, when researchers at the Queen Victoria Hospital of Sussex, England were able to restore the sight of forty people using the same technique. The group, led by Sheraz Daya, was able to successfully use adult stem cells obtained from the patient, a relative, or even a cadaver. Further rounds of trials are ongoing.

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Why is SR9009 prohibited in sport?

Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.

How is SR9009 detected in samples?

Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.

How should SR9009 be stored?

Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.

Network